- Zacks
Novo Nordisk (NVO) to Invest $4.1B in Clayton Facility Expansion
Novo Nordisk (NVO) plans to invest $4.1 billion in order to expand its Clayton facility with a second manufacturing plant, boosting capacity for injectable treatments and creating 1,000 new jobs.
- Zacks
Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals
Alnylam (ALNY) soars as its phase III study, seeking to expand Anvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy, achieves primary and all secondary endpoints.
- Zacks
Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.
© 2024 Yahoo. All rights reserved.